Meds A-Z
Marbofloxacin
Detailed information about Marbofloxacin
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
What it does:
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis ex...
When it's needed:
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Call your vet sooner if you notice:
- Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Commonly reported reactions:
- (2 reports)
- (1 reports)
- (1 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Marbofloxacin
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: MSK
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200761 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141598 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
- High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 2 | |
| 1 | Cat | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (23) Dog (9)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-048791
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 13 • Secondary summaries: 0
- FOI Summary oA 200-761 Approved January 29, 2026.pdf · FOI
- Cronoquin™ Tablets · SPL
- FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf · FOI
- Otiserene® · SPL
- FOI Summary oA 200-736 Approved January 13, 2023.pdf · FOI
- Marbofloxacin · SPL
- FOI Summary oA 200-733 Approved January 12, 2023.pdf · FOI
- Marbofloxacin Chewable Tablets · SPL
- FOI Summary oA 200-586 Approved March 23, 2020.pdf · FOI
- Marboquin™ · SPL
- ucm117199.pdf · FOI
- ucm117196.pdf · FOI
- Zeniquin® · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17971 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18330/Cronoquin%E2%84%A2%20Tablets · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16805 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17106/Otiserene%C2%AE · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13375 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13532/Marbofloxacin · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13365 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13525/Marbofloxacin%20Chewable%20Tablets · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/8507 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/8509/Marboquin%E2%84%A2 · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:03 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 11695-7010-1 | 11695 | - | |
| 11695-7010-2 | 11695 | - | |
| 11695-7011-1 | 11695 | - | |
| 11695-7011-2 | 11695 | - | |
| 11695-7012-1 | 11695 | - | |
| 11695-7013-1 | 11695 | - | |
| 13612-0033-0 | 13612 | - | |
| 13612-0033-1 | 13612 | - | |
| 17033-013-10 | 17033 | - | |
| 17033-013-25 | 17033 | - | |
| 17033-014-10 | 17033 | - | |
| 17033-014-25 | 17033 | - | |
| 17033-015-50 | 17033 | - | |
| 17033-016-50 | 17033 | - | |
| 46066-171-32 | 46066 | - | |
| 46066-171-33 | 46066 | - | |
| 46066-173-32 | 46066 | - | |
| 46066-173-33 | 46066 | - | |
| 46066-175-31 | 46066 | - | |
| 46066-176-31 | 46066 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI Summary oA 200-761 Approved January 29, 2026.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 200761
-
FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf
• FOI summary • Official
• June 3, 2025
FDA FOI summary for application 141598
-
FOI Summary oA 200-736 Approved January 13, 2023.pdf
• FOI summary • Official
• Feb. 1, 2023
FDA FOI summary for application 200736
-
FOI Summary oA 200-733 Approved January 12, 2023.pdf
• FOI summary • Official
• Feb. 1, 2023
FDA FOI summary for application 200733
-
FOI Summary oA 200-586 Approved March 23, 2020.pdf
• FOI summary • Official
• April 1, 2020
FDA FOI summary for application 200586
-
ucm117196.pdf
• FOI summary • Official
• Feb. 12, 2019
FDA FOI summary for application 141151
-
ucm117199.pdf
• FOI summary • Official
• Feb. 12, 2019
FDA FOI summary for application 141151
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Anorexia, Other ab… (Official, 2026-02-12)
- usage: For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Cronoquin™ Tablets
RX
Marbofloxacin
Tablet
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-761 | Approved | Feb 2, 2026 |
|
Otiserene®
RX
Dexamethasone Marbofloxacin Terbinafine
Otic Suspension
• Otic
|
Dechra, Ltd. | NADA 141-598 | Approved | Jun 3, 2025 |
|
Marbofloxacin
RX
Marbofloxacin
Tablet
• Oral
|
ZYVET AH, Inc. | ANADA 200-736 | Approved | Feb 1, 2023 |
|
Marbofloxacin Chewable Tablets
RX
Marbofloxacin
Chewable Tablets
• Oral
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-733 | Approved | Feb 1, 2023 |
|
Marboquin™
RX
Marbofloxacin
Tablet
• Oral
|
Dechra Veterinary Products LLC | ANADA 200-586 | Approved | Apr 1, 2020 |
|
Zeniquin®
RX
Marbofloxacin
Tablet
• Oral
|
Zoetis Inc. | NADA 141-151 | Approved | Feb 12, 2019 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius) in dogs.
Administer one dose (1 tube) per affected ear once.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.
For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.
For the treatment of urinary tract infections, Marboquin™ tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin.
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
Summary
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
- Cronoquin™ Tablets (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius) in dogs.
- Otiserene® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
- Marbofloxacin (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
- Marboquin™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm117199.pdf
Summary
Provides for the use of Zeniquin (marbofloxacin) tablets in cats.
-
FOI ucm117196.pdf
Summary
Zeniquin ™ (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin.
- Zeniquin® (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 14 and Cat 14 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, ['Retriever - Labrador', 'Terrier - Airedale'], Female, 4 year, 37.83 kilogram • Drug: MSK, Tablet, Oral, Dose: 100 Milligram per animal • Reactions: Lack of efficacy - NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055106
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 4.00 Year
- Weight: 37.830 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 100 Milligram per animal
Dog, Bulldog - English, Male, 6.4 year, 26.76 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Lack of efficacy - NOS • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-050472
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 6.40 Year
- Weight: 26.760 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Unassigned
Cat, Crossbred Feline/cat, Female, 16.67 year, 2.631 kilogram • Drug: MSK, Unknown • Reactions: Seizure NOS • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-049550
- Serious AE: Yes
- Treated For AE: No
- Sex: Female
- Age: 16.67 Year
- Weight: 2.631 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Cat, Domestic Shorthair, Female, 16 year • Drug: MSK, Unknown • Reactions: Ketosis, Hyperglycaemia • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-048331
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 16.00 Year
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Cat, Maine Coon, Male, 11 year, 4.4 kilogram • Drug: MSK, Tablet, Oral • Reactions: Weight loss, Vomiting, Diarrhea, Increased drinking, Elevated alanine aminotransferase… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-048791
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 11.00 Year
- Weight: 4.400 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
Dog, Poodle - Standard, Female, 3 year • Drug: MSK, Tablet, Oral • Reactions: Vomiting • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-046985
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 3.00 Year
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
Dog, Bulldog - American, Male, 11 year, 37.467 kilogram • Drug: MSK, Tablet, Oral, Dose: 150 Milligram per animal, Frequency: 1 per day • Reactions: Seizure NOS, Abdominal pain, Constipation, Abnormal ultrasound finding, Death by euthanasia… • Outcome: Euthanized
- Report ID: USA-USFDACVM-2025-US-046987
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 11.00 Year
- Weight: 37.467 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 150 Milligram per animal
- Frequency: 1 per day
Cat, Himalayan, Female, 9 year, 3.58 kilogram • Drug: MSK, Unknown • Reactions: Not eating • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-044875
- Serious AE: No
- Treated For AE: Yes
- Sex: Female
- Age: 9.00 Year
- Weight: 3.580 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.